Pfizer 'breakthrough' gain may speed needed meningococcal B vaccine
This article was originally published in Scrip
Executive Summary
Just days after a Drexel University student in Philadelphia died of serogroup B meningococcal disease – the same strain that has been linked to an outbreak at Princeton University in nearby New Jersey – the FDA granted Pfizer breakthrough therapy designation for its experimental vaccine candidate bivalent rLP2086.